Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276717 · ClinicalTrials.gov registry record · Phase 1
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01276717 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 20 participants.
The verdict
NCT01276717, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This will be a phase I study of carfilzomib in combination with vorinostat in patients with relapsed/refractory B-cell lymphomas. Combination therapy with proteosome inhibitor PR-171 and HDAC inhibitors is highly synergistic in primary DLBCL cells, and both classes of drugs can also synergize powerfully to induce cell death in bortezomib-resistant cells. The purpose of this study is to see if vorinostat can combine with carfilzomib and to safely find the recommended phase II dose.
Interventions
- DRUG Vorinostat
- DRUG Drug: Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276717
The ClinicalTrials.gov registry entry for NCT01276717 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT01276717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276717 about?
NCT01276717 is a clinical study titled "Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma". This will be a phase I study of carfilzomib in combination with vorinostat in patients with relapsed/refractory B-cell lymphomas. Combination therapy with proteosome inhibitor PR-171 and HDAC inhibitors is highly synergistic in primary DLBCL cells, and both classes of drugs can also synergize powerf...
What is the current status of trial NCT01276717?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01276717?
The interventions under investigation include: Vorinostat (DRUG), Drug: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01276717?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.